Key result
This editorial highlights recent research on cardiovascular risk estimation, emphasizing the validation of risk models, the role of genetic and environmental factors, and stepwise prevention strategies.
Answers are grounded in this paper and cite their sources.
This editorial summarizes recent research on cardiovascular risk estimation, highlighting the utility of integrating genetic, imaging, and environmental factors into traditional risk models.
This issue of the European Journal of Preventive Cardiology focuses on the implementation of cardiovascular risk estimation and its prevention and treatment. In a study conducted in Ontario, Canada, researchers evaluated the new SCORE2 risk prediction1 models within a contemporary primary prevention cohort. Sud et al.2 found that the SCORE2-OP models applied to 57,409 individuals aged 40–69 years demonstrated moderate-to-good discrimination, with excellent calibration when using uncalibrated models, but worsening calibration when using models originally calibrated for low-risk regions (overestimating risk by 100% in women and 36% in men). Calibration in older populations improved when using models calibrated for low-risk regions, particularly in men, but remained suboptimal in women, overestimating risk by 60% in women and 13% in men. The study emphasizes the importance of validating SCORE2 models before integrating them into routine clinical practice. The overestimation of risk, particularly in women, suggests the need for careful consideration of the rescaling parameters, especially in regions with different risk profiles such as Canada. Birhanu et al.3 conduct a comprehensive evaluation of cardiovascular (CV) risk prediction tools [World Health Organization Risk Score (WHO-RS) tools, Australian Risk Score (ARS), and Global risk (Globorisk)] within the rural Indian population, specifically within the framework of the Rishi Valley Prospective Cohort Study. Among 2333 participants, the 5-year observed risk was 4.4%. The WHO-RS tools underestimated CV risk, but the ARS overestimated risk, particularly in men. Globorisk tools showed relatively good discrimination and agreement. Øvretveit et al.4 investigate the association between polygenic risk scores (PRSs) and blood pressure traits throughout different stages of life. Polygenic risk scores, which consider multiple genetic factors, were analysed in relation to blood pressure in a large-scale study. The research found significant associations between PRS and blood pressure across various age groups, indicating a potential role of genetics in influencing blood pressure regulation over the lifespan and consequently cardiac and renal disease. These findings highlight the importance of considering genetic factors in understanding blood pressure variations across different ages. The study aims to assess the predictive value of adding coronary artery calcium score (CACS) and a genetic risk score (GRS) to a traditional risk model for predicting CV events (SCORE2).5 The results demonstrated that incorporating both CACS and GRS significantly improved the predictive accuracy of the traditional risk model in a cohort of 1002 asymptomatic subjects free of clinical coronary disease and diabetes mellitus (DM). Specifically, the addition of CACS and GRS enhanced the ability to identify individuals at higher risk of experiencing CV events compared with the traditional risk model alone. This suggests that integrating CACS and GRS into CV risk assessment models could enhance risk prediction and aid in identifying individuals who may benefit from targeted prevention strategies or interventions. The study examines the influence of CACS on CV disease (CVD), coronary heart disease (CHD), and all-cause death in over 5000 younger adults with metabolic syndrome (MetS) and DM, from the Coronary Artery Risk Development in Young Adults and Multi-Ethnic Study of Atherosclerosis registries. Over a median follow-up of 14.2 years, CACS was independently associated with incident CVD in those with DM [hazard ratio (HR): 1.22), MetS (HR: 1.18), and neither condition (HR: 1.36). Similar associations for CHD and death were found. However, the association of coronary artery calcium (CAC) ≥ 100 with CVD and CHD events was less pronounced in the presence of DM.6 This systematic review and meta-analysis explore the relationship between lipoprotein(a) [Lp(a)] levels and the presence of CAC in asymptomatic patients. Lipoprotein(a) is a type of lipoprotein that has been implicated in the development of atherosclerosis and CVD. The study aims to aggregate and analyse existing research on this topic to determine whether there is a significant association between elevated Lp(a) levels and the presence of CAC, which is a marker of coronary artery disease. By systematically reviewing 18 studies and pooling data of 23 105 patients, Martignoni et al.7 demonstrated that asymptomatic patients with elevated Lp(a) had 31% higher chances of having any coronary calcification (CAC > 0) and 29% higher chances of having more advanced calcification (CAC > 100). Age is a significant risk factor for both CV and non-CV degenerative diseases. However, not everyone ages at the same rate, leading to the concept of biological age. Genetics, environment, and lifestyle influence biological age, causing some individuals to be younger or older than their chronological age. Heart structural and functional changes occur with advancing age. The hypothesis is that associations of age with structural and functional echocardiographic traits would allow the detection of different biological ageing rates of the heart and assess their prognostic role. In a study involving 2614 healthy individuals, researchers investigated the relationship between age and various echocardiographic parameters (left atrial size, diastolic dysfunction, and left ventricle hypertrophy). They identified three distinct patterns of heart ageing: ‘slow’, ‘normal’, and ‘accelerated’. These patterns were associated with different rates of CV events. Additionally, a proxy measure of biological age, called HeartPhAge, was found to differ significantly from chronological age across the different ageing patterns. Specifically, individuals with a slow ageing pattern had an HeartPhAge of 9 years younger, while those with an accelerated pattern were estimated as 4 years older compared with their chronological age.8 The article by Jiang et al.9 delves into the complex relationship between exposure to multiple air pollutants, genetic predisposition, and the risk of myocardial infarction (MI). Conducted through a cohort analysis of 329 189 UK Biobank participants without MI at baseline, the study seeks to elucidate how combined environmental and genetic factors contribute to the onset of MI. The research examines the influence of various air pollutants, such as particulate matter, nitrogen dioxide, and ozone, on the risk of MI. Additionally, the study investigates how individual genetic susceptibility, as indicated by specific genetic markers or PRS, interacts with air pollutant exposure to modulate MI risk. Participants with the highest PRS and air pollution score possessed the highest risk of incident MI (HR = 4.88, 95% confidence interval 4.35–5.47). Integrating PRS, air pollution exposure, and traditional factors substantially improved risk prediction of MI. This research letter10 investigates the intricate relationship between environmental temperature and blood pressure phenotypes through a comprehensive nationwide study utilizing home blood pressure monitoring. It aims to discern how variations in temperature across different regions impact various aspects of blood pressure. Barbosa et al. propose that in regions with warmer temperatures, individuals with elevated office blood pressure (OBP) should be more closely monitored for white-coat hypertension (WCH), where blood pressure readings are higher in a clinical setting than at home. Conversely, in colder regions, individuals with normal OBP should be monitored for masked hypertension (MH), where blood pressure readings appear normal in a clinical setting but are actually elevated at home. The study suggests that considering external temperature could improve the diagnosis of blood pressure phenotypes and it is crucial when formulating public health policies for preventing and managing hypertension. This is especially important in colder cities where higher rates of MH and WCH are observed, as these phenotypes are associated with increased CV risk. 2021 ESC Prevention Guidelines1 suggest a stepwise approach for residual CV risk in patients with established atherosclerotic CVD. For Step 1, the recommendations include maintaining LDL-cholesterol (LDLc) levels below 1.8 mmol/L, systolic blood pressure (SBP) below 140 mmHg, using any antithrombotic medication, sodium glucose co-transporter 2 inhibition, and smoking cessation. For Step 2, the recommendations involved stricter targets, such as maintaining LDLc levels below 1.4 mmol/L, SBP below 130 mmHg, considering dual-pathway inhibition with aspirin plus low-dose rivaroxaban, using colchicine, glucagon-like peptide-1 receptor agonists, and eicosapentaenoic acid. These recommendations aimed to provide a structured approach to managing CV risk factors in patients with established atherosclerotic CVD, with Step 2 reflecting more intensive treatment strategies for those at higher risk. Holtrop et al.11 found that with the conventional treatments of Step 1, the risk of CVD remains high, with a 10-year risk of new events higher than 10% in the vast majority of patients. The intensive treatment options of Step 2 allow up to 63% of patients to achieve a 10-year risk of new CVD below 10%. The article explores the role of ideal CV health (CVH) metrics (such as blood pressure, cholesterol levels, smoking status, physical activity, diet, and body mass index) in reducing the risk of incident arrhythmias. Analysing data from the Atherosclerosis Risk in Communities cohort, with participants recruited from four different communities across the USA, the authors conclude that intermediate and ideal levels of CVH metrics are associated with a markedly reduced risk of developing incident arrhythmias, including atrial fibrillation/flutter, ventricular arrhythmias, and bradyarrhythmia, independent of CHD.12
No takes yet. Share an insight, caveat, or question.
Guida et al. (2024) conducted an editorial in Cardiovascular disease. Cardiovascular risk estimation and prevention was evaluated. This editorial highlights recent research on cardiovascular risk estimation, emphasizing the validation of risk models, the role of genetic and environmental factors, and stepwise prevention strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: